Bristol Myers Squibb
Search results
Celgene is a biopharmaceutical company that makes cancer and immunology drugs, such as Revlimid and Abraxane. It was founded in 1986 and became a subsidiary of Bristol Myers Squibb in 2019 after several acquisitions and collaborations.
Nov 20, 2019 · Bristol-Myers Squibb completed its merger with Celgene in November 2019, creating a leading biopharmaceutical company with diverse and promising pipelines. The transaction involved a stock-and-cash deal, a divestiture of OTEZLA, and an accelerated share repurchase program.
Jan 3, 2019 · Bristol-Myers Squibb and Celgene announce a cash and stock merger with an equity value of $74 billion. The combined company will create a leading biopharma company with complementary portfolios in oncology, immunology, inflammation and cardiovascular disease.
To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the REMS products THALOMID ® (thalidomide), POMALYST ® (pomalidomide), REVLIMID ® (lenalidomide) and generic lenalidomide.
Jan 4, 2019 · Bristol-Myers Squibb Co <BMY.N> said on Thursday it would buy Celgene Corp <CELG.O> for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest...
Nov 20, 2019 · Bristol-Myers Squibb Co. has closed its deal to buy Celgene Corp., one of the largest in pharmaceutical history. The merger combines nine products with more than $1 billion in annual sales and creates a leading biopharma company.
Jan 3, 2019 · Bristol-Myers Squibb agreed to acquire Celgene for about $74 billion, creating a cancer-drug powerhouse, but one with questions about its long-term prospects.
